6[1]El-Agnaf OM,Paleologou KE,Greer B,et al.A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson′s disease and related disorders.FASEB J,2004,18:1315-1317.
7[2]Gilman S,Low PA,Quinn N,et al.Consensus statement on the diagnosis of multiple system atrophy.J Neurol Sci,1999,163:94-98.
8[3]Graham J,Oppenheimer D.Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy.J Neurol Neurosurg Phychiatry,1969,32:28-34.
9[4]Armstrong RA,Cairns NJ,Lantos PL.A quantitative study of the pathological changes in ten patients with multiple system atrophy(MSA).J Neural Transm,2004,111:485-495.
10[7]Horimoto Y,Aiba I,Yasuda T,et al.Cerebral atrophy in multiple system atrophy by MRI.J Neurol Sci,2000,173:109-112.
